Idrebormilast
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Idrebormilast
- Molecular weight
- 327.19
- Structure (SMILES)
- CCCOc1cc(-c2cncc([C@@H]3COB(O)C3)c2)ccc1OC
- idrebormilast
- Idrebormilast
- idrebormilast [INN]
- IDREBORMILAST [USAN]
- idrebormilast inn
- idrebormilast usan
- pf 07038124
- pf 07038124 ointment
- pf 07038124 who dd
- Pf-07038124
- PF-07038124
- PF-07038124 [WHO-DD]
- PF-07038124 ointment
- pf07038124
- PF07038124
- CAS registry numbers
- 2415085-44-6
- ChEMBL ID
- CHEMBL6056273
- InChIKey
- KXVKOYCGACSUPP-INIZCTEOSA-N
- PubChem compound IDs
- 148293990
- FDA ingredient codes (UNII)
- M6ZU548FWD
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- PF-07038124
- Type
- Synthetic organic
- Drug name stem
- -ast
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- phosphodiesterase 4B
- Gene symbol
- PDE4B
- Protein identifier
- Q07343
- Median affinity
- 9.3
- Affinity units
- pIC50
- Condition
- Psoriasis
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000676
- Subject identifier
- D011565
- Condition
- Dermatitis
- Highest recorded phase
- 1
- Condition identifier
- HP:0011123
- Subject identifier
- D003872
- Condition identifier
- EFO_0000274
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000676
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001494
- Highest recorded phase
- 2
- Condition identifier
- HP_0011123
- Condition identifier
- MONDO_0002406
- Condition identifier
- MONDO_0004980
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005083
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006608
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008661
- Highest recorded phase
- 2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Heavy atoms
- 24
- Molecular formula
- C18H22BNO4
- Monoisotopic mass
- 327.1641883
- Natural product
- No
- Recorded assays
- 3
- Active assays
- 3
Active assay types
- Confirmatory
Related records
Trials (6)
- A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants
- A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
- PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea
- Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo
- Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis
- Study to Evaluate the Safety, Local and Systemic Tolerability, and Pharmacokinetics of Multiple-Dose Topical Administration of PF-07038124 in Japanese Healthy Participants
In development for (5)
- Atopic eczema Phase 2
- Dermatitis Phase 1
- Psoriasis Phase 1
- Seborrheic dermatitis Phase 2
- Vitiligo Phase 2